Fundz

Viridian Therapeutics, Inc. Appoints Stephen Mahoney as Chief Executive Officer

PUBLIC · VRDNOct 30, 2023

Company

Viridian Therapeutics

WalthamBiotechnologyHealth CareTherapeutics

Description

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that Stephen Mahoney has been appointed the company’s President and Chief Executive Officer, and a member of the Board of Directors, effective immediately.

Other recent leadership changes in Therapeutics and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Viridian Therapeutics, and when

A new leader at Viridian Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Viridian Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Viridian Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Viridian Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Viridian Therapeutics

Location

Waltham, Massachusetts, United States

About

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian's most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED).

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Viridian Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Stephen
Likely contact at this company
••••••••@••••••••

See Stephen's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Viridian Therapeutics's next move

Learn about Strategic plan

Viridian Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.